Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.55 |
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836404 | 0.99 | FOLH1 (0.57) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL12836738 | 0.95 | FOLH1 (0.58) | FOLH1NOD1GLP1R | |
| SCHEMBL15003787 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL21417883 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL20018413 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL20018407 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL12836737 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL22237179 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL18030076 | 0.91 | FOLH1 (0.67) | FOLH1NOD1GLP1REPHX2 | |
| SCHEMBL18059393 | 0.90 | FOLH1 (0.69) | FOLH1NOD1GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064657-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064657-A1 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS | FOLH1, PHOSPHO1, KLK3 | FOLH1 1/4885NOD1 4238/4885GLP1R 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.